Cited by 263Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

Kim, Sehee, Moon, Minho, Park, Seungjoon·2009·Journal of Endocrinology

DOI 10.1677/joe-09-0132

Open this paper in CoChat — free account

Abstract

Exendin-4 is a naturally occurring more potent and stable analog of glucagon-like peptide-1 (GLP-1) that selectively binds at the GLP-1 receptor. It has been recently demonstrated that GLP-1 receptor stimulation preserves dopaminergic neurons in cellular and rodent models of Parkinson's disease (PD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes nigrostriatal dopaminergic neurotoxicity in rodents; previous studies suggest that activated microglia actively participate in the pathogenesis of PD neurodegeneration. However, the role of microglia in the neuroprotective properties of exendin-4 is still unknown. Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers. Exendin-4 prevents MPTP-induced microglial activation in the SNpc and striatum, and the expression of matrix metalloproteinase-3. In addition, exendin-4 also suppressed MPTP-induced expression of pro-inflammatory molecules and tumor necrosis factor α and interleukin-1β. Our data indicate that exendin-4 may act as a survival factor for dopaminergic neurons by functioning as a microglia-deactivating factor and suggest that exendin-4 may be a valuable therapeutic agent for neurodegenerative diseases such as PD.

Integrity signals

Registry

Crossref · 10.1677/joe-09-0132

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,889
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 4×
“Microglia-derived NO-mediated nitrate stress plays a pivotal role in the pathogenesis of PD, which is supported by the demonstration that MPTP-induced SNpc dopaminergic neuron loss and the production of ventral midbrain nitrotyrosine are attenuated in mice lacking the iNOS gene (Liberatore et al. 1999).”
Influential
Cytotoxicity of microglia
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993) · Glia · doi:10.1002/glia.440070117 · Cited by 1,032
MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
González-Scarano, F., & Baltuch, G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.219 · Cited by 984
Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP.
D'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892

Flagged first, then by citations

Show all 55 references

Sorted by citations

Items 101–200 of 263

The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01
Lv, M., Xue, G., Cheng, H.-F., Meng, P., Lian, X., Hölscher, C., & Li, D. (2021) · Brain and Behavior · doi:10.1002/brb3.2231 · Cited by 63
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 63
The non‐peptide GLP ‐1 receptor agonist WB 4‐24 blocks inflammatory nociception by stimulating β ‐endorphin release from spinal microglia
Fan, H. J., Gong, N., Li, T., Ma, A., Wu, X., Wang, M., & Wang, Y. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12895 · Cited by 60
Incretin‐based therapies
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 65
Drug Repurposing in Parkinson’s Disease
Athauda, D. S., & Foltynie, T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0548-y · Cited by 59
Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
Onoviran, O. F., Li, D., Smith, S. T., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 64
Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines
Ventorp, F., Bay-Richter, C., Nagendra, A. S., Janelidze, S., Matsson, V. S., Lipton, J., Nordström, U., Westrin, Å., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171068 · Cited by 56
Orientin Inhibits HMGB1-Induced Inflammatory Responses in HUVECs and in Murine Polymicrobial Sepsis
Yoo, H., Ku, S., Lee, T., & Bae, J. (2014) · Inflammation · doi:10.1007/s10753-014-9899-9 · Cited by 55
Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy
Bu, L.-L., Liu, Y., Shen, Y., Fan, Y., Yu, W., Jiang, D., Tang, Y., Yang, Y., Wu, P., Zuo, C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01018-5 · Cited by 54
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats
Badawi, G. A., Fattah, M. A. A. E., Zaki, H. F., & Sayed, M. I. E. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-9998-3 · Cited by 53
Morroniside, a secoiridoid glycoside from Cornus officinalis ,attenuates neuropathic pain by activation of spinal glucagon‐like peptide‐1 receptors
Xu, M., Wu, H., Liu, H., Gong, N., Wang, Y., & Wang, Y. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13720 · Cited by 52
Thiamine and Parkinson's disease
Lương, K. V. Q., & Nguyễn, L. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.02.008 · Cited by 50
Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease
Aksoy, D., Solmaz, V., Çavuşoğlu, T., Meral, A., Ateş, U., & Erbaş, O. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.05.002 · Cited by 51
Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model
Zhang, Y., Chen, Y., Li, L., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.021 · Cited by 50
Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson’s disease by regulating gut microbiota
Zhang, Y., Xu, S., Qian, Y., Mo, C., Ai, P., Yang, X., & Xiao, Q. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1099018 · Cited by 51
Combined melatonin and exendin‐4 therapy preserves renal ultrastructural integrity after ischemia–reperfusion injury in the male rat
Yip, H., Yang, C., Chen, K., Huang, T., Chen, Y., Zhen, Y., Sung, P., Chiang, H., Sheu, J., Chang, C., et al. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12273 · Cited by 49
Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic
Foltynie, T., & Avilés-Olmos, I. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.005 · Cited by 50
Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders
Yang, X., Wang, Y., Wu, C., & Ling, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181031122438 · Cited by 49
Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress
Lin, T., Lin, K.-J., Lin, H., Lin, K.-L., Lan, M., Wang, P., Wang, T., Wang, F., Tsai, P.-C., Liou, C., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 50
Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System
Chiou, H.-Y. C., Lin, M., Hsiao, P., Chen, C., Chiao, S., Lin, T.-Y., Chen, Y., Wu, D.-C., & Lin, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071584 · Cited by 52
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T., Tovar‐y‐Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury
Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar‐y‐Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 48
Parkinson’s Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
Dixit, T. S., Sharma, A. N., Lucot, J. B., & Elased, K. M. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.03.008 · Cited by 46
The novel protective effects of loganin against 1‐methyl‐4‐phenylpyridinium‐induced neurotoxicity: Enhancement of neurotrophic signaling, activation of IGF‐1R/GLP‐1R , and inhibition of RhoA/ROCK pathway
Tseng, Y., Lin, W., Chang, W., & Lo, Y. (2018) · Phytotherapy Research · doi:10.1002/ptr.6259 · Cited by 46
Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review
Koshal, P., Jamwal, S., & Kumar, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.015 · Cited by 45
Activated Immune Cells in Parkinson's Disease
Cao, J., Li, K., & Shen, Y. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9280-9 · Cited by 44
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
Foltynie, T., & Athauda, D. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 46
DA5‐CH and Semaglutide Protect against Neurodegeneration and Reduce α‐Synuclein Levels in the 6‐OHDA Parkinson’s Disease Rat Model
Zhang, L., Li, C., Zhang, Z., Zhang, Z., Jin, Q., Li, L., & Hölscher, C. (2022) · Parkinson s Disease · doi:10.1155/2022/1428817 · Cited by 45
The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems
Nakmode, D. D., Day, C. M., Song, Y., & Garg, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051503 · Cited by 48
Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments
Brundin, P., Barker, R. A., Conn, P. J., Dawson, T. M., Kieburtz, K. D., Lees, A. J., Schwarzschild, M. A., Tanner, C. M., Isaacs, T., Duffen, J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-139000 · Cited by 42
DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship
Alrouji, M., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Elekhnawy, E., & Batiha, G. E. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00500-5 · Cited by 41
Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma
Lawrence, E. C. N., Guo, M., Schwartz, T. D., Wu, J. J., Lu, J., Nikonov, S. S., Sterling, J. K., & Cui, Q. N. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1156829 · Cited by 43
The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets
Ascoli, B. M., Géa, L. P., Colombo, R., Barbé‐Tuana, F. M., Kapczinski, F. P., & Rosa, A. R. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416642846 · Cited by 40
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease
Hansen, H. H., Fabricius, K., Barkholt, P., Mikkelsen, J. D., Jelsing, J., Pyke, C., Knudsen, L. B., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.038 · Cited by 40
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 42
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 38
Effects of Exenatide on Metabolie Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model
Sun, L., Cheng, J., Jin, L., Bi, Y., Feng, W., Li, P., Shen, S., & Zhu, D. (2016) · Reproductive Sciences · doi:10.1177/1933719116635278 · Cited by 37
Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Wang, S., Wu, S., Chen, T.-C., & Chuang, C. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134805 · Cited by 39
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
Jung, Y. J., Tweedie, D., Scerba, M. T., Kim, D. S., Palmas, M. F., Pisanu, A., Carta, A. R., & Greig, N. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656921 · Cited by 37
Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway
Jia, Y., Gong, N., Li, T., Zhu, B., & Wang, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.008 · Cited by 36
Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Rane, P., Sarmah, D., Bhute, S., Kaur, H., Goswami, A., Kalia, K., Borah, A., Dave, K. R., Sharma, N., & Bhattacharya, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00180 · Cited by 35
Lamiophlomis herba: A comprehensive overview of its chemical constituents, pharmacology, clinical applications, and quality control
Li, Y., Fang, L., Zheng, T., Shi, L., Zhang, Z., Niu, T., Wang, Q., Zhao, D., Li, W., & Zhao, P. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112299 · Cited by 36
Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches
Khor, S. L. Q., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330093829 · Cited by 37
Glucagon-like peptide-1 protects the murine hippocampus against stressors via Akt and ERK1/2 signaling
Yoshino, Y., Ishisaka, M., Tsujii, S., Shimazawa, M., & Hara, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.098 · Cited by 34
Plant Polyphenols and Exendin-4 Prevent Hyperactivity and TNF-α Release in LPS-Treated In vitro Neuron/Astrocyte/Microglial Networks
Gullo, F., Ceriani, M., D’Aloia, A., Wanke, E., Constanti, A., Costa, B., & Lecchi, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00500 · Cited by 36
Sustained Release GLP‑1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Wang, V., Kuo, T., Huang, E. Y., Ma, K., Chou, Y., Fu, Z.-Y., Lai, L.-W., Jung, J. H., Choi, H.-I., Choi, D., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00013 · Cited by 35
Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy
Zhou, L., Xu, Z., Oh, Y., Gamuyao, R., Lee, G., Xie, Y., Cho, H., Lee, S., & Duh, E. J. (2021) · JCI Insight · doi:10.1172/jci.insight.93382 · Cited by 34
p38β Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial β-Endorphin Expression
Wu, H., Mao, X.-F., Fan, H. J., & Wang, Y. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107102 · Cited by 34
Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
Bader, M., Li, Y., Lecca, D., Rubovitch, V., Tweedie, D., Glotfelty, E. J., Rachmany, L., Kim, H. K., Choi, H., Hoffer, B. J., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.023 · Cited by 34
Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions
Shandilya, A., & Mehan, S. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05328-6 · Cited by 34
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 32
Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics
Lis, M., Stańczykiewicz, B., Liśkiewicz, P., & Misiak, B. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104744 · Cited by 34
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats
Fujita, S., Ushio, S., Ozawa, N., Masuguchi, K., Kawashiri, T., Oishi, R., & Egashira, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141921 · Cited by 32
RETRACTED: Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 32
Retracted
Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Gargiulo, S., Gamba, P., Poli, G., & Leonarduzzi, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660701 · Cited by 34
Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin
Abdelwahed, O. M., Tork, O. M., el Din, M. G., Rashed, L. A., & Zickri, M. B. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.002 · Cited by 34
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway
Fan, S., Xiong, Q., Wang, L., Zhang, L., & Shi, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111005 · Cited by 30
Deciphering variability in the role of interleukin-1β in Parkinson’s disease
Saghazadeh, A., Ferrari, C. C., & Rezaei, N. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0059 · Cited by 30
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 28
Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: Focus on glucagon-like peptide-1 receptor agonists
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 31
Semaglutide Protects against 6‐OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
Liu, D.-X., Zhao, C.-S., Wei, X., Ma, Y.-P., & Wu, J.-K. (2022) · Parkinson s Disease · doi:10.1155/2022/6813017 · Cited by 27
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 30
Exendin-4-assisted adipose derived mesenchymal stem cell therapy protects renal function against co-existing acute kidney ischemia-reperfusion injury and severe sepsis syndrome in rat.
Sung, P., Chiang, H., Wallace, C. G., Yang, C., Chen, Y.-T., Chen, K., Chen, C., Shao, P., Chen, Y., Chua, S. O., et al. (2017) · PubMed Central · Cited by 26
Exenatide and Sitagliptin Decrease Interleukin 1β, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.
Moraes, R. M., Lima, G. M. G., Oliveira, F. E., Brito, A. C. V., Pereira, R. C., Oliveira, L. D., Barros, P. P., Franco, G. C., & Anbinder, A. (2015) · The Journal of Periodontology · doi:10.1902/jop.2015.150278 · Cited by 21
Role of Vitamin D in Parkinson’s Disease
Lương, K. V. Q., & Nguyễn, L. (2012) · ISRN Neurology · doi:10.5402/2012/134289 · Cited by 25
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 25
Myeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 25
Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease
Maanvi, Kumari, S., & Deshmukh, R. R. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175426 · Cited by 23
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 52
Self-citation
Gut-Brain Communication in Parkinson’s Disease: Enteroendocrine Regulation by GLP-1
Manfready, R. A., Forsyth, C. B., Voigt, R. M., Hall, D. A., Goetz, C. G., & Keshavarzian, A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01196-5 · Cited by 24
Retracted: Exendin‐4 reverts behavioural and neurochemical dysfunction in a pre‐motor rodent model of Parkinson's disease with noradrenergic deficit
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02100.x · Cited by 22
Retracted
Enhanced protection against renal ischemia–reperfusion injury with combined melatonin and exendin-4 in a rodent model
Chang, Y., Hsu, S.-Y., Yang, C., Sung, P., Chen, Y., Huang, T., Kao, G., Chen, S., Chen, K., Chiang, H., et al. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216642528 · Cited by 22
Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease
Sancandi, M., Schul, E. V., Economides, G., Constanti, A., & Mercer, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00479 · Cited by 22
Brain Damage - Bridging Between Basic Research and Clinics
González-Quevedo, A. (2012) · InTech eBooks · doi:10.5772/2174 · Cited by 21
Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease
Verma, A., Chaudhary, S., Solanki, K., Goyal, A., & Yadav, H. N. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14426 · Cited by 21
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 25
Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease.
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Cited by 19
Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
Manfready, R. A., Engen, P. A., Metman, L. V., Sanzo, G., Goetz, C. G., Hall, D. A., Forsyth, C. B., Raeisi, S., Voigt, R. M., & Keshavarzian, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.660942 · Cited by 24
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
Jones-Tabah, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167927 · Cited by 18
The Anti-Inflammatory Effects of Glucagon-Like Peptide Receptor Agonist Lixisenatide on the Retinal Nuclear and Nerve Fiber Layers in an Animal Model of Early Type 2 Diabetes
Chung, Y. W., Lee, J., Lee, J. Y., Ju, H. H., Lee, Y., Jee, D. H., Ko, S., & Choi, J. A. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.011 · Cited by 18
Combined therapy with melatonin and exendin-4 effectively attenuated the deterioration of renal function in rat cardiorenal syndrome.
Chen, K., Chen, C., Wallace, C. G., Chen, Y.-T., Yang, C., Sung, P., Chiang, H., Chen, Y., Chua, S. O., Yip, H., et al. (2017) · Europe PMC (PubMed Central) · Cited by 18
Imaging neuroinflammation in Alzheimer’s and other dementias: recent advances and future directions
Brooks, D. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.049 · Cited by 17
Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease
Liu, C. Z., Guo, D. S., Ma, J. J., Dong, L. R., Chang, Q., Yang, H. Q., Liang, K., Li, X. H., Yang, D., Fan, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.889257 · Cited by 19
Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease
Verma, A., & Goyal, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176936 · Cited by 17
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development
Majumdar, M., & Badwaik, H. R. (2024) · Current Drug Targets · doi:10.2174/0113894501312703240826070530 · Cited by 16
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus
O'Brien, J. T., Chouliaras, L., Sultana, J., Taylor, J., Ballard, C. G., on behalf of the RENEWAL Study Group, Aarsland, D., Blanc, F., Boeve, B. F., Brooks, D. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01103-7 · Cited by 17
Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice
Huang, Y., Wang, X., Li, W., Yue, F., Wang, M., & Zhou, F. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479670 · Cited by 16
Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia
Umegaki, H. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0375-0 · Cited by 17
Animal venoms: therapeutic tools for tackling Parkinson’s disease
Amaral, H. D. O., Monge‐Fuentes, V., Mayer, A. B., Campos, G. A. A., Lopes, K. S., Camargo, L. C., Schwartz, M. F., Galante, P., & Mortari, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.004 · Cited by 17
Parkinson’s disease and the gut-brain connection: unveiling pathways, mechanisms and promising therapies
Hajare, S., & Kulkarni, Y. A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149975 · Cited by 18
Exendin-4 protected against critical limb ischemia in obese mice.
Sheu, J., Chang, M., Wallace, C. G., Chiang, H., Sung, P., Tsai, T., Chung, S., Chen, Y., Chua, S. O., Chang, H., et al. (2015) · PubMed Central · Cited by 15
Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents
Patel, B., Greenland, J. C., & Williams‐Gray, C. H. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240353 · Cited by 20
Protective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Pathology of Neurodegenerative Diseases
Kim, Y. S., Kim, Y.-K., Hwang, O., & Dong, J. (2012) · InTech eBooks · doi:10.5772/38028 · Cited by 16
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Dou, X., Zhao, L., Li, J., & Jiang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1537898 · Cited by 16
Neuroprotective role of (Val 8 ) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
Liu, Y., Li, L., Liu, K., Zhao, J., Hölscher, C., & Li, G. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177742 · Cited by 14

Authors: Kim, S., Moon, M., & Park, S.
Affiliations: Kyung Hee University (KR)
Corresponding author: Park, Seungjoon
ORCID: Kim, Sehee
Moon, Minho
Venue: Journal of Endocrinology
Publisher: Bioscientifica
Published: 2009-06-29
Volume: 202
Issue: 3
Pages: 431-439
ISSN: 0022-0795 (ISSN-L)
1479-6805
DOI: 10.1677/joe-09-0132
OpenAlex: W2164948885
Cited by: 263
References: 55
Citations by year: 2026: 6 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 21 · 2021: 22 · 2020: 12 · 2019: 18 · 2018: 20 · 2017: 17 · 2016: 22 · 2015: 19 · 2014: 17 · 2013: 17 · 2012: 15
FWCI: 6.18
Type: journal article
Language: en
Open access: closed
Locations: Journal of Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: Korea Science and Engineering Foundation
Ministry of Education and Human Resources Development
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: exendin-4, Parkinson's disease, dopaminergic neurons, microglial activation, matrix metalloproteinase-3, MPTP-induced neurotoxicity, substantia nigra pars compacta, neuroprotection, GLP-1 receptor, neuroinflammation, TNF-α, IL-1β, nigrostriatal degeneration
MeSH terms: Exenatide, Animals, Corpus Striatum, Disease Models, Animal, Dopamine, Gliosis, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Peptides, Substantia Nigra, Venoms, Gene Expression Regulation, Enzymologic, Microglia, Neuroprotective Agents, Inflammation Mediators, Matrix Metalloproteinase 3, Parkinsonian Disorders, Mice, Matrix Metalloproteinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks